Eurotrials Selects Merge eClinical as Clinical Research Technology Partner
May 19 2014 - 7:00AM
Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of
innovative enterprise imaging, interoperability and clinical
systems that seek to advance healthcare, today announced that
Eurotrials, a full-service clinical research organization with
expertise in Europe and Latin America, has selected Merge as its
technology partner of choice to focus on expanding their presence
in Europe and the burgeoning Latin American market.
As part of the agreement, Merge will create a data center in
Brazil to serve Eurotrials' researchers in the region and train
them as certified providers of the company's solution, Merge
eClinical OS™ (eCOS), a unified platform utilizing a pay-as-you-go,
self-run environment to manage and run studies.
Dr. Maria Queiroz, Global CEO with Eurotrials, said the
partnership makes sense on a number of levels. "First and foremost,
both our firms thrive on cultivating a climate of collaboration and
innovation to serve the needs of a fast-evolving market. eCOS
enables Eurotrials to help our clients stay on top of new trends in
risk assessment such as remote and risk-based monitoring."
According to Dr. Queiroz, the integration of functions such as
embedded translation, automatic medical coding and electronic
patient reported outcomes in eCOS significantly boosts her firm's
ability to manage studies across borders seamlessly. "And the fact
that eCOS empowers data managers with no programming experience to
design studies on their own is extraordinarily valuable," she
said.
"One of our primary goals in 2014 is to expand our international
business, and we couldn't have found a better partner for this
effort. We are honored and excited to partner with a company of
Eurotrials' profile and prestige," said Zaher El-Assi, President of
Merge eClinical. "Our eCOS solution has a strong presence in the
U.S. and European markets and we certainly expect to see continued
growth in those regions."
Justin Dearborn, CEO of Merge, continued, "A key strategy for us
is penetrating markets where advanced clinical study management
technologies such as eCOS are not yet commonplace. Joining forces
with a prominent CRO that is universally recognized for its
expertise in Latin America is a huge benefit for Merge and will
allow us to continue to expand our global footprint."
About Eurotrials
Eurotrials is a privately owned full-service CRO focused in
Europe and Latin America markets with strong local expertise. The
company has been validated by international biopharmaceutical
companies, has several master agreements and is ISO- 9001
certified. With nearly 20 years of experience, Eurotrials has
offices in Portugal, Brazil, Argentina, Chile and Spain and
presence in Peru, Colombia, Mexico and several European countries.
Eurotrials provides an extensive array of services from early- to
late-stage research as well as product support in accordance with
global and specific regional requirements. Innovative models of
collaboration with the biopharmaceutical and device industry,
research institutions and clinical research sites are the main
drivers of Eurotrials' development strategy.
About Merge
Merge is a leading provider of innovative enterprise imaging,
interoperability and clinical systems that seek to advance
healthcare. Merge's enterprise and cloud-based technologies for
image intensive specialties provide access to any image, anywhere,
any time. Merge also provides clinical trials software with
end-to-end study support in a single platform and other intelligent
health data and analytics solutions. With solutions that have been
used by providers for more than 25 years, Merge is helping to
reduce costs, improve efficiencies and enhance the quality of
healthcare worldwide. For more information, visit merge.com and
follow us @MergeHealthcare.
Cautionary Notice Regarding Forward-Looking
Statements
The matters discussed in this news release may include
forward-looking statements, which could involve a number of risks
and uncertainties. When used in this press release, the words
"will," "believes," "intends," "anticipates," "expects" and similar
expressions are intended to identify forward-looking statements.
Actual results could differ materially from those expressed in, or
implied by, such forward-looking statements. Except as expressly
required by the federal securities laws, the Company undertakes no
obligation to update such factors or to publicly announce the
results of any of the forward-looking statements.
CONTACT: Media Contacts:
Aaron Mazze
Merge eClinical
+1 919.653.3467
aaron@eclinicalos.com
Claudia Carvalho
Eurotrials Scientific Consultants
(+351) 213 825 457
claudia.carvalho@eurotrials.com
Mirage Energy (PK) (USOTC:MRGE)
Historical Stock Chart
From May 2024 to Jun 2024
Mirage Energy (PK) (USOTC:MRGE)
Historical Stock Chart
From Jun 2023 to Jun 2024